2. Song P, Xu Y, Zha M, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors.
J Glob Health 2019;9:010427.
3. McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review.
Ophthalmology 2010;117:1113-23.
4. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia.
Ophthalmology 2010;117:313-9.
5. Hayreh SS. Management of central retinal vein occlusion.
Ophthalmologica 2003;217:167-88.
6. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion.
Ophthalmology 2011;118:119-33.
7. Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of central retinal vein occlusion.
J Clin Med 2020;9:3457.
8. Dysli C, Enzmann V, Sznitman R, Zinkernagel MS. Quantitative analysis of mouse retinal layers using automated segmentation of spectral domain optical coherence tomography images.
Transl Vis Sci Technol 2015;4:9.
9. Podkowinski D, Philip AM, Vogl WD, et al. Neuroretinal atrophy following resolution of macular oedema in retinal vein occlusion.
Br J Ophthalmol 2019;103:36-42.
10. Kim HJ, Yoon HG, Kim ST. Correlation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusion.
Int J Ophthalmol 2018;11:256-61.
11. Ota M, Tsujikawa A, Ojima Y, et al. Retinal sensitivity after resolution of the macular edema associated with retinal vein occlusion.
Graefes Arch Clin Exp Ophthalmol 2012;250:635-44.
12. Ebneter A, Agca C, Dysli C, Zinkernagel MS. Investigation of retinal morphology alterations using spectral domain optical coherence tomography in a mouse model of retinal branch and central retinal vein occlusion.
PLoS One 2015;10:e0119046.
13. Tsai G, Banaee T, Conti FF, Singh RP. Optical coherence tomography angiography in eyes with retinal vein occlusion.
J Ophthalmic Vis Res 2018;13:315-32.
14. Lee MW, Lee WH, Ryu CK, et al. Peripapillary retinal nerve fiber layer and microvasculature in prolonged type 2 diabetes patients without clinical diabetic retinopathy.
Invest Ophthalmol Vis Sci 2021;62:9.
16. Lee MW, Lee WH, Ryu CK, et al. Effects of prolonged type 2 diabetes on the inner retinal layer and macular microvasculature: an optical coherence tomography angiography study.
J Clin Med 2020;9:1849.
17. Tatlipinar S, Dinc UA, Yenerel NM, Gorgun E. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
Clin Exp Optom 2012;95:94-8.
18. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.
Invest Ophthalmol Vis Sci 2012;53:6214-8.
19. Tilton RG, Chang KC, LeJeune WS, et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.
Invest Ophthalmol Vis Sci 1999;40:689-96.
21. Foxton RH, Finkelstein A, Vijay S, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.
Am J Pathol 2013;182:1379-90.
22. Joltikov KA, de Castro VM, Davila JR, et al. Multidimensional functional and structural evaluation reveals neuroretinal impairment in early diabetic retinopathy.
Invest Ophthalmol Vis Sci 2017;58:BIO277-90.
24. Feher J, Taurone S, Spoletini M, et al. Ultrastructure of neurovascular changes in human diabetic retinopathy.
Int J Immunopathol Pharmacol 2018;31:394632017748841.
25. Stem MS, Talwar N, Comer GM, Stein JD. A longitudinal analysis of risk factors associated with central retinal vein occlusion.
Ophthalmology 2013;120:362-70.
26. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion.
Am J Ophthalmol 2001;131:61-77.
27. Koizumi H, Ferrara DC, Brue C, Spaide RF. Central retinal vein occlusion case-control study.
Am J Ophthalmol 2007;144:858-63.
28. Sodi A, Giambene B, Marcucci R, et al. Atherosclerotic and thrombophilic risk factors in patients with ischemic central retinal vein occlusion.
Retina 2011;31:724-9.
29. Kuo JZ, Lai CC, Ong FS, et al. Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality.
Retina 2010;30:479-84.
30. O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis.
Arch Ophthalmol 2008;126:692-9.
32. Akay F, Gundogan FC, Yolcu U, et al. Choroidal thickness in systemic arterial hypertension.
Eur J Ophthalmol 2016;26:152-7.
33. Kase S, Endo H, Takahashi M, et al. Alteration of choroidal vascular structure in diabetic retinopathy.
Br J Ophthalmol 2020;104:417-21.
34. Kim KM, Lee MW, Lim HB, et al. Repeatability of measuring the vessel density in patients with retinal vein occlusion: an optical coherence tomography angiography study.
PLoS One 2020;15:e0234933.
35. Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema.
JAMA Ophthalmol 2014;132:1309-16.
36. Kang HM, Chung EJ, Kim YM, Koh HJ. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion.
Graefes Arch Clin Exp Ophthalmol 2013;251:501-8.
37. Shin HJ, Chung H, Kim HC. Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion.
Acta Ophthalmol 2011;89:e35-40.